CENCORA, INC. (COR) FY2026 Q3 Statement of Cash Flows

Income StatementCash FlowBalance Sheet

Statement of Cash Flows

2026-04-01 to 2026-06-30

Swipe to see the full flow
CENCORA, INC. cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Calculated remaining financing cash flows are purple; remaining operating and investing bundles are gray. Their underlying inflows and outflows are not separately identified. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Net income → Net cash from operating activities: $776,667,000.00Accounts payable → Operating adjustments reconciliation: $2,827,267,000.00Depreciation, including amounts charged to cost of goods sold → Operating adjustments reconciliation: $154,410,000.00Amortization, including amounts charged to interest expense → Operating adjustments reconciliation: $123,018,000.00Prepaid expenses and other assets → Operating adjustments reconciliation: $107,734,000.00Adjustments to RCA and OneOncology equity units → Operating adjustments reconciliation: $55,167,000.00Provision for deferred income taxes → Operating adjustments reconciliation: $54,884,000.00Accrued expenses → Operating adjustments reconciliation: $36,138,000.00Share-based compensation expense → Operating adjustments reconciliation: $28,733,000.00Income taxes payable and other liabilities → Operating adjustments reconciliation: $17,363,000.00Türkiye highly inflationary impact → Operating adjustments reconciliation: $15,724,000.00Provision for credit losses → Operating adjustments reconciliation: $11,721,000.00Gain on remeasurement of equity investment → Operating adjustments reconciliation: $6,000,000.00Gain on sale of assets → Operating adjustments reconciliation: $1,282,000.00Operating adjustments reconciliation → Net cash from operating activities: $1,877,393,000.00Operating adjustments reconciliation → Inventories: $886,857,000.00Operating adjustments reconciliation → Accounts receivable: $445,946,000.00Operating adjustments reconciliation → Long-term accrued litigation liability: $103,894,000.00Operating adjustments reconciliation → LIFO credit: $94,304,000.00Operating adjustments reconciliation → (Gain) loss on divestiture of businesses: $17,247,000.00Operating adjustments reconciliation → Other, net: $13,800,000.00Remaining investing cash flows, net (calculated) → investing reconciliation: $27,043,000.00Other, net → investing reconciliation: $6,963,000.00Non-customer note receivable → investing reconciliation: $2,813,000.00investing reconciliation → Capital expenditures: $226,039,000.00investing reconciliation → Cost of acquired companies, net of cash acquired: $41,660,000.00investing reconciliation → Cost of equity investments: $9,269,000.00Net cash used in financing activities → financing reconciliation: $1,767,825,000.00Borrowings under revolving and securitization credit facilities → financing reconciliation: $12,884,288,000.00Senior notes and loan borrowings → financing reconciliation: $39,328,000.00financing reconciliation → Repayments under revolving and securitization credit facilities: $12,852,175,000.00financing reconciliation → Purchases of common stock: $1,000,052,000.00financing reconciliation → Senior notes and loan repayments: $719,646,000.00financing reconciliation → Cash dividends on common stock: $116,589,000.00financing reconciliation → Other, net: $2,841,000.00financing reconciliation → Employee tax withholdings related to restricted share vesting: $138,000.00Net cash used in investing activities → investing reconciliation: $240,149,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $2,236,262,000.00Net cash from operating activities → Cash sources and uses: $2,654,060,000.00Cash sources and uses → Other changes in cash (calculated): $17,391,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $2,864,957,000.00Cash sources and uses → Net cash used in investing activities: $240,149,000.00Cash sources and uses → Net cash used in financing activities: $1,767,825,000.00Income taxes payable and other liabilities: $17,363,000.00Income taxes payable & other+$17.36 M(Gain) loss on divestiture of businesses: -$17,247,000.00Business sale gain & loss−$17.25 MNet income: $776,667,000.00Net income+$776.67 MAmortization, including amounts charged to interest expense: $123,018,000.00Amortization expense+$123.02 MPrepaid expenses and other assets: $107,734,000.00Prepaid & other assets+$107.73 MProvision for credit losses: $11,721,000.00Credit loss provision+$11.72 MDepreciation, including amounts charged to cost of goods sold: $154,410,000.00Depreciation expense+$154.41 MAccounts receivable: -$445,946,000.00Accounts receivable−$445.95 MProvision for deferred income taxes: $54,884,000.00Deferred income taxes+$54.88 MOther, net: -$13,800,000.00Other non-cash items−$13.80 MShare-based compensation expense: $28,733,000.00Stock-based compensation+$28.73 MAdjustments to RCA and OneOncology equity units: $55,167,000.00Contingent consideration change+$55.17 MTürkiye highly inflationary impact: $15,724,000.00Türkiye inflationary impact+$15.72 MLIFO credit: -$94,304,000.00Inventory reserve provision−$94.30 MAccounts payable: $2,827,267,000.00Accounts payable+$2.83 BGain on remeasurement of equity investment: $6,000,000.00Equity remeasurement gain+$6.00 MInventories: -$886,857,000.00Inventories−$886.86 MAccrued expenses: $36,138,000.00Accrued liabilities+$36.14 MImpairment of assets, including goodwill: $0.00Gain on sale of assets: $1,282,000.00Other asset gain & loss+$1.28 MRemeasurement gain related to OneOncology acquisition (Note 2): $0.00Long-term accrued litigation liability: -$103,894,000.00Long-term litigation accrual−$103.89 MGain on divestiture of equity investment: $0.00Net cash from operating activities: $2,654,060,000.00Operating cash+$2.65 BOperating adjustments reconciliation: $3,439,441,000.00Senior notes and loan repayments: -$719,646,000.00Long-term debt repaid−$719.65 MSenior notes and loan borrowings: $39,328,000.00Debt issued+$39.33 MBorrowings under revolving and securitization credit facilities: $12,884,288,000.00Credit line borrowings+$12.88 BCash dividends on common stock: -$116,589,000.00Common dividends paid−$116.59 MRepayments under revolving and securitization credit facilities: -$12,852,175,000.00Credit line repayments−$12.85 BOther, net: -$2,841,000.00Other financing, net−$2.84 MEmployee tax withholdings related to restricted share vesting: -$138,000.00Stock-award tax withholding−$138.00 KPurchases of common stock: -$1,000,052,000.00Equity repurchases−$1.00 BNet cash used in financing activities: -$1,767,825,000.00. Cash required to fund net payments.Financing cash−$1.77 Bfinancing reconciliation: $14,691,441,000.00Capital expenditures: -$226,039,000.00PP&E purchases−$226.04 MCost of acquired companies, net of cash acquired: -$41,660,000.00Acquisitions, net of cash−$41.66 MOther, net: $6,963,000.00Other investing, net+$6.96 MNon-customer note receivable: $2,813,000.00Non-customer note receivable+$2.81 MCost of equity investments: -$9,269,000.00Equity-method investments made−$9.27 MRemaining investing cash flows, net (calculated): $27,043,000.00Remaining investing (calculated)+$27.04 MNet cash used in investing activities: -$240,149,000.00. Cash required to fund net payments.Investing cash−$240.15 Minvesting reconciliation: $276,968,000.00Cash sources and uses: $4,890,322,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $2,236,262,000.00Beginning cash$2.24 BEnding cash: Cash, cash equivalents, and restricted cash: $2,864,957,000.00Ending cash$2.86 BOther changes in cash (calculated): -$17,391,000.00Other changes in cash(calculated)−$17.39 MCASH RECONCILIATIONOperatingflowsInvestingflowsFinancingflowsFree cash flow$2.43 BOperating cash − cash spent on PP&ECash flow / Net income3.42×Operating cash flow ÷ net incomeNet cash change+$628.70 MEnding cash − beginning cash
Chart details

CENCORA, INC. cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026

Cash flows for Apr 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Mar 31, 2026. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Mar 31, 2026
2,236,262,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
2,654,060,000 US dollars. Net cash provided.
Income taxes payable and other liabilities
17,363,000 US dollars
(Gain) loss on divestiture of businesses
negative 17,247,000 US dollars
Net income
776,667,000 US dollars
Amortization, including amounts charged to interest expense
123,018,000 US dollars
Prepaid expenses and other assets
107,734,000 US dollars
Provision for credit losses
11,721,000 US dollars
Depreciation, including amounts charged to cost of goods sold
154,410,000 US dollars
Accounts receivable
negative 445,946,000 US dollars
Provision for deferred income taxes
54,884,000 US dollars
Other, net
negative 13,800,000 US dollars
Share-based compensation expense
28,733,000 US dollars
Adjustments to RCA and OneOncology equity units
55,167,000 US dollars
Türkiye highly inflationary impact
15,724,000 US dollars
LIFO credit
negative 94,304,000 US dollars
Accounts payable
2,827,267,000 US dollars
Gain on remeasurement of equity investment
6,000,000 US dollars
Inventories
negative 886,857,000 US dollars
Accrued expenses
36,138,000 US dollars
Impairment of assets, including goodwill
0 US dollars
Gain on sale of assets
1,282,000 US dollars
Remeasurement gain related to OneOncology acquisition (Note 2)
0 US dollars
Long-term accrued litigation liability
negative 103,894,000 US dollars
Gain on divestiture of equity investment
0 US dollars
Investing activities
negative 240,149,000 US dollars. Net cash used. The remaining amount is calculated by subtracting the other displayed items from the investing total. This quarter is the year to date less the prior quarter's year to date. The prior quarter reported part of this section under different lines (Proceeds from sale of assets), so Proceeds from divestiture of a business and Proceeds from sale of assets cannot be separated for this quarter. It may combine inflows and outflows.
Capital expenditures
negative 226,039,000 US dollars
Cost of acquired companies, net of cash acquired
negative 41,660,000 US dollars
Other, net
6,963,000 US dollars
Non-customer note receivable
2,813,000 US dollars
Cost of equity investments
negative 9,269,000 US dollars
Remaining investing cash flows, net (calculated)
27,043,000 US dollars
Financing activities
negative 1,767,825,000 US dollars. Net cash used.
Senior notes and loan repayments
negative 719,646,000 US dollars
Senior notes and loan borrowings
39,328,000 US dollars
Borrowings under revolving and securitization credit facilities
12,884,288,000 US dollars
Cash dividends on common stock
negative 116,589,000 US dollars
Repayments under revolving and securitization credit facilities
negative 12,852,175,000 US dollars
Other, net
negative 2,841,000 US dollars
Employee tax withholdings related to restricted share vesting
negative 138,000 US dollars
Purchases of common stock
negative 1,000,052,000 US dollars
Operating adjustment reconciliation
3,439,441,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
14,691,441,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing displayed reconciliation
276,968,000 US dollars. Intermediate calculation joining the displayed items and the calculated net remainder. It does not establish gross cash receipts or payments and is not an additional cash flow.
Exchange-rate effect
0 US dollars
Other changes in cash (calculated)
negative 17,391,000 US dollars. Out of cash; drawn as the small gray flow above ending cash.
Ending cash on Jun 30, 2026
2,864,957,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
4,890,322,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
628,695,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
3.42×. Operating cash flow divided by reconciliation net income for the same period. Black from 0.90× through 1.10×; green above 1.10×; red below 0.90×. Color uses the unrounded ratio.
Operating cash flow
2,654,060,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
226,039,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
2,428,021,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net income enters operating cash directly in the reconciliation. The adjustment junction contributes the remaining $1.88B after reconciling the other positive and negative adjustments. These connections depict an accounting reconciliation, not traced cash receipts.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 2,654,060,000 US dollars minus 226,039,000 US dollars equals 2,428,021,000 US dollars.
CENCORA, INC. (COR) FY2026 Q3 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!